Supreme Plants 3000 Wappa Cannabis Plants as Production to Ramp to 5 Million Grams

Supreme Commences Production in New Flowering Rooms

 

TORONTO, Nov. 7, 2017 /CNW/ – Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (TSXV: FIRE) is pleased to announce 7ACRES has commenced production in the newly constructed flowering rooms recently approved by Health Canada. Yesterday, over 3,000 plants of a specially selected phenotype of cannabis called “Wappa” were hand-transplanted into the first of three 10,000 sq. ft. flowering rooms. Wappa was selected for the inaugural planting due to its favourable early-stage market feedback, growth characteristics and terpene content. The transplanting was completed in a single-day process, required to ensure the uniformity of the end product. The remaining 20,000 sq. ft. will be fully planted over the balance of November 2017, increasing 7ACRES’ anticipated annual output capacity to over 5,000 kg per year.

One of three new 10,000 sq. ft. flowering rooms at the 7ACRES Hybrid Facility (CNW Group/Supreme Pharmaceuticals Inc.)

Today marks an important growth milestone for 7ACRES as Canada’s leading cultivation-focused Licensed Producer.  Adding an additional 30,000 sq. ft. of flowering rooms quadruples our production capacity and moves us closer to achieving our goal of growing premium quality cannabis flowers at scale.

John Fowler, CEO of Supreme

The additional output increases our ability to establish national strategic partnerships with Licensed Producers that are seeking to provide Canadian patients with premium cannabis. As well, the expansion also represents the next step in scaling 7ACRES in preparation for the Canadian adult use market.

Supreme anticipates the first harvests from the additional flowering rooms will be completed in the first quarter of calandar 2018.

Licensed Producers and/or ACMPR applicants interested in procuring premium quality dried cannabis flowers or trim may contact wholesale@7ACRES.com.

About Supreme

Supreme is a Canadian publicly traded company established as the leading premium cultivator and distributor of sun grown cannabis through its wholly-owned subsidiary 7ACRES. 7ACRES is a federally licensed producer of medical cannabis pursuant to the ACMPR operating inside a 342,000 sq. ft. hybrid-facility. This facility combines the best technology of indoor production with the efficiencies and sustainability of a greenhouse, in a single large-format production footprint. Please visit supreme.ca and 7ACRES.com for more information.

Original press release

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter